(601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 601607 · · 23 pages · Chinese
Summary by 6ix AI
The report confirms the accuracy and completeness of its contents, with the board of directors taking legal responsibility for the information provided. Key financial data indicates a slight increase in revenue compared to the previous year, while net profit has seen a decline. The company continues to advance its new drug pipeline and strengthen its innovation ecosystem, with significant investments in research and development.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Shanghai Pharmaceuticals Holding Co. Ltd. on 6ix
Earlier from Shanghai Pharmaceuticals
- (601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Progress of Drug Clinical Trials
- (601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Convening the Q3 2026 Performance Briefing
- (601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Approval for Production of Clevidipine Emulsion Injection
- (601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Transfer of Equity Interests in Zeus Investment Limited and Its Affiliates
- (601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Annual Operating Performance Assessment and Compensation Plan for Senior Executives
Later from Shanghai Pharmaceuticals
- (601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Completion of Private Investment Fund Filing for the SIIC Biomedical Industry Private Fund Established with the Company's Participation
- (601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Receipt of Clinical Trial Approval Notice for Treprostinil Diethanolamine Inhalation Powder
- (601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Shareholding Increase Plan of Controlling Shareholder
Follow Shanghai Pharmaceuticals into a list and get an email when it puts out news.
Follow Shanghai Pharmaceuticals